Corvus Pharmaceuticals, Inc.
- CRVS
- NASDAQ
- Biotechnology
- Immuno-Oncology
- Anti-CD73 Antibody
- Cancer Immunotherapy
$9.66
Today +1.47%Quote Oct 19, 2026, 02:04 PM UTC
−24.14%over the last month
Max drawdown −30.2%From 1-month high −29.2%3 months −32.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$812.6M
Quote Oct 19
Next earnings
Nov 3
Expected, not confirmed
Analyst target
$33.17
+243.4% from here
Floor
$9.17
5.1% below price
Where the price sits
13 analysts
Analyst range, low to high
$27.00$42.00
- Price $9.66
- Resistance $9.84
- Consensus $33.17
The price is right under resistance. Analysts' average target sits about 243% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CRVSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
37
Founded
2014